The results showed that FBXO22 was expressed at a higher level in AML patients harboring t(11q23)/MLL in comparison with AML subtypes with t(8;21), t(15;17), inv(16)/t(16;16), inv(3)/t(3;3), complex cytogenetics and other cytogenetics except for AML with normal karyotype in TCGA-LAML cohort (Additional file 2: Fig. S1F) and Beat-AML cohort (Additional file 2: Fig. S1G). Here, FBXO22 is linked to acute myeloid leukemia.